Novartis Completes Acquisition of Regulus Therapeutics in $1.7 Bn Deal
By
Novartis has completed its acquisition of Regulus Therapeutics, a San Diego, California-based clinical-stage bio/pharmaceutical company developing microRNA therapeutics, in a deal worth up to $1.7 billion ($800 million upfront and…